Skip to main content

Aptorum Group (US:APM) — Company Overview, News & Financial Data

Aptorum Group  logo
APMAptorum Group
Aptorum Group  primary media
Company profile

Aptorum Group

Aptorum Group (NASDAQ:APM) is a dynamic biopharmaceutical company dedicated to developing and commercializing a diverse range of innovative therapeutic and diagnostic technologies targeting unmet medical needs. With a strategic focus on infectious diseases and oncology, among other fields, Aptorum is actively engaged in advancing its pipeline through rigorous research and development efforts. They are committed to leveraging cutting-edge science and technology to provide new solutions that can significantly improve patient outcomes and quality of life. Their objective is to lead the way in discovering and developing novel therapeutics and diagnostics that address the critical challenges faced by patients around the globe.

Snapshot

Public USOwnership
2010Year founded
15Employees
London, EnglandHead office
Loading Map...
Global footprint

Operations

All Locations

Products and/or services of Aptorum Group

  • Smart Pharma - Utilizes artificial intelligence for drug discovery and development processes.
  • SACT-1 - A repurposed drug aimed at treating neuroblastoma.
  • ALS-4 - An antimicrobial for Staphylococcus aureus infections, including MRSA.

Aptorum Group executive team

  • Mr. Chung Yuen HuenFounder, CEO & Executive Director
  • Mr. Kwok Kuen WongHead of Finance